In addition, the acquisition of drug-resistance associated with tumor heterogeneity has been reported to involve dynamic phenotypic switching with cells transiently acquiring drug-resistance via chromatin-modifications leading to activation of IGF-I receptor (IGF-IR) signaling (79). The gene discussed is IGF1R; the disease is neoplasm.